Metastasis

Artera Announces Three Presentations at ASCO 2024 That Demonstrate the Reliability and Depth of its AI Cancer Platform

Retrieved on: 
fredag, maj 31, 2024
Oncology, Health, Technology, Other Science, Clinical Trials, Artificial Intelligence, Science, Eosin, Patient, Prognosis, Biochemistry, Risk, H&E, MMAI, Molecular biology, Algorithm, Recurrence, Breast cancer, MD, AI, Prostate cancer, Pathology, Cancer, Biomarker, Abstract, Haematoxylin, Metastasis, Thought, Medical imaging

These studies build upon the first AI-enabled test that delivers prognostic and predictive insights for localized prostate cancer patients: ArteraAI Prostate Test .

Key Points: 
  • These studies build upon the first AI-enabled test that delivers prognostic and predictive insights for localized prostate cancer patients: ArteraAI Prostate Test .
  • “Currently, cancer care strongly emphasizes biochemistry and molecular biology, and advancements can take decades to develop and adopt.
  • Artera’s model offers a novel way of thinking, utilizing AI and image analysis to significantly fast-track innovation and advancements in cancer care, demonstrating performance across diverse patient cohorts.
  • “This approach to cancer research has the potential to transform the future of cancer care."

Gilead Provides Update on Phase 3 TROPiCS-04 Study

Retrieved on: 
torsdag, maj 30, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Hospitals, Clinical Trials, Patient, Progression-free survival, Survival, TPC, UC, Bladder cancer, G-CSF, Diagnosis, FDA, PFS, Breast cancer, ADC, Ageing, ITT, Death, Metastasis, OS, Physician, MUC, Infection, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC).

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC).
  • The study did not meet the primary endpoint of overall survival (OS) in the intention-to-treat (ITT) population.
  • Gilead is continuing to analyze the data and will discuss the results and next steps with the FDA.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials, including the TROPiCS-04 study.

Sarah Cannon Research Institute to Present Latest Cancer Research Insights at 2024 ASCO® Annual Meeting

Retrieved on: 
torsdag, maj 30, 2024
Research, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Relapse, Follicular lymphoma, Paclitaxel, Finish line, Drug development, Metastatic breast cancer, Breast cancer, Tumor microenvironment, Sarah Cannon Research Institute, Breast, Lead, Master, Consolidation, HealthOne, Durvalumab, Meta-analysis, CDT, OU Health, Total cost, PD-L1, Survival, Clinical trial, Quality, MPH, Endometrial cancer, NSCLC, SCRI, ASCO, Safety, BCMA, Society, Cetuximab, Doctor of Philosophy, Efficacy, Spacecraft, Metastasis, Monoclonal antibody, Acute myeloid leukemia, Abstract, HCA Healthcare, Role, Annual general meeting, Birth control

“We look forward to connecting with colleagues from around the world at ASCO’s Annual Meeting to discuss the latest developments in advancing therapies for cancer patients,” says Howard A.

Key Points: 
  • “We look forward to connecting with colleagues from around the world at ASCO’s Annual Meeting to discuss the latest developments in advancing therapies for cancer patients,” says Howard A.
  • To learn more about our research experts, visit our Leadership Page .
  • “Clinical Trial Participation and End-of-Life Care Among Older Adults: A Multi-Center Longitudinal Observational Cohort Analysis of 121,717 Patients with Cancer,” Dr.
  • “Performance of Comprehensive Genomic Profiling versus Single Gene Testing in Guideline-Recommended Biomarker Selection in Non-Small Cell Lung Cancer,” Dr. V. Subbiah, 1:30 p.m. - 4:30 p.m. CDT, Hall A.

Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance

Retrieved on: 
torsdag, maj 30, 2024
Oncology, Health, Genetics, Other Health, Research, Science, Biotechnology, Patient, Survival, Biology, Risk, Neoplasm, Cancer, CNS, ASCO, Society, Central nervous system, Metastasis, Annual general meeting, Nursing

Key take-aways: Cutaneous melanoma (CM) metastasis to the central nervous system (CNS) has a poor prognosis; however, patients generally experience better outcomes if CNS metastases are detected and treated earlier when the patient is still asymptomatic.

Key Points: 
  • Key take-aways: Cutaneous melanoma (CM) metastasis to the central nervous system (CNS) has a poor prognosis; however, patients generally experience better outcomes if CNS metastases are detected and treated earlier when the patient is still asymptomatic.
  • CNS imaging is not routinely recommended for patients with early-stage CM (American Joint Committee on Cancer 8th edition (AJCC8) stage I–II), yet approximately 14% of patients with stage II melanoma will develop CNS metastases.
  • This study demonstrated that the DecisionDx-Melanoma test can identify patients with earlier-stage melanoma who have a higher risk of CNS metastasis within the first three years post-diagnosis.
  • These higher-risk patients may benefit from more frequent imaging surveillance to identify CNS metastases earlier to improve patient survival.

New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis

Retrieved on: 
onsdag, maj 29, 2024
Research, Genetics, Biotechnology, Other Health, Radiology, Health, Pharmaceutical, Science, Oncology, Radiation therapy, Patient, Acceleration, Risk, Physics, Neoplasm, MFS, Cone Health Women's Hospital, ART, NCCN, National Comprehensive Cancer Network, Canadian International Council, Hospital, Risk factor, SCC, Risk assessment, Metastasis, Medical imaging

A DecisionDx-SCC Class 2B result was the only independent risk factor that successfully identified patients who would most benefit from ART.

Key Points: 
  • A DecisionDx-SCC Class 2B result was the only independent risk factor that successfully identified patients who would most benefit from ART.
  • Class 2B patients who received ART showed a significant deceleration in disease progression compared to Class 2B patients who did not receive ART.
  • DecisionDx-SCC identified patients who were less likely to show a significant benefit from ART in controlling disease progression.
  • Given the low risk of metastasis for Class 1 patients, in addition to the lower likelihood of ART benefit, Class 1 patients may consider deferring treatment.

MEDSIR & Debiopharm Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer

Retrieved on: 
tisdag, maj 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, Patient, Infection, Prognosis, WEE1, HER2, Clinical trial, University, Diagnosis, AACR, Safety, Breast cancer, Sacituzumab govitecan, ADC, Gilead Sciences, HR, Breast, Metastasis, Cell, Mortality, IST, PR, University of Bristol, TNBC, Pharmaceutical industry

Hormone receptor-positive (HR+)/HER2- is the most common type of breast cancer and it accounts for 70% of all breast cancers.

Key Points: 
  • Hormone receptor-positive (HR+)/HER2- is the most common type of breast cancer and it accounts for 70% of all breast cancers.
  • “It’s great to see companies like Debiopharm that are open to investigating novel combination strategies to support breast cancer patients.
  • “We are honored to develop this Investigator Sponsor Trial (IST) in collaboration with Debiopharm and Gilead to explore new approaches to breast cancer treatment.
  • The foundations for this clinical trial were set by the promising preclinical data suggesting an existing synergy between Debiopharm’s Debio 0123 and Gilead’s sacituzumab govitecan.

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

Retrieved on: 
fredag, maj 24, 2024
Merck & Co., Progression-free survival, Pembrolizumab, Kaplan–Meier estimator, CFS, Toxicity, Metastasis, Bladder cancer, Carcinoma, FDA, PFS, Safety, Fast track (FDA), MD, ITT, ASCO, Merck, CIS, NMIBC, Society, Carcinoma in situ, Dor, Annual general meeting, Pharmaceutical industry

The data will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting from May 31-June 4, in Chicago, IL.

Key Points: 
  • The data will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting from May 31-June 4, in Chicago, IL.
  • “There is a significant unmet need for new and innovative treatments for patients suffering with bladder cancer.
  • As of May 17, 2024, the CR rate in the ITT population at 24 months was 54% (19/35) (95% CI, 37-71%).
  • To learn more about the results from BOND-003 you may read the Company’s press release issued on May 3, 2024.

Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
torsdag, maj 23, 2024
Uveal melanoma, Patient, Sentinel lymph node, Risk, RP2, Clinical trial, Safety, RP1, ASCO, Abstract, Society, Nivolumab, SLN, Metastasis, Pharmaceutical industry

WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced multiple presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 31-June 4, 2024.

Key Points: 
  • WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced multiple presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 31-June 4, 2024.
  • Details for the presentations are as follows:
    Abstract Title: Efficacy and safety of RP1 combined with nivolumab in patients with anti-PD-1 failed melanoma from the IGNYTE clinical trial.
  • Data included in the presentation will be 12-month investigator-assessed data with a cutoff date of March 8, 2024, as compared to the abstract which includes 6-month investigator-assessed data.
  • As previously disclosed, the topline 12-month primary analysis results by independent central review are expected later in Q2 2024.

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

Retrieved on: 
torsdag, maj 23, 2024
MPH, ICI, Patient, Doctor of Philosophy, Survival, University of Pennsylvania, Metastasis, Clinical trial, University, CADL, Therapy, Neoplasm, Valaciclovir, Disease, Safety, Fast track (FDA), Pancreatic cancer, ASCO, Injection, Society, CD8, Lung cancer, Standard of care, SOC, Annual general meeting, Pharmaceutical industry

Together, these data continue to support the emerging differentiated profile of CAN-2409 in this difficult-to-treat condition.

Key Points: 
  • Together, these data continue to support the emerging differentiated profile of CAN-2409 in this difficult-to-treat condition.
  • “The results from our phase 2 trial in NSCLC continue to support the tremendous promise of CAN-2409 across multiple solid tumors.
  • We are particularly encouraged by the overall survival observed in the patients whose disease had progressed despite receiving prior anti-PD-(L)1 treatment.
  • “The data reported today suggest that CAN-2409 can reactivate these patients’ exhausted immune systems, including those with low PD-(L)1 expression.

Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer

Retrieved on: 
torsdag, maj 23, 2024
Nervous system, Patient, AMIX, Liver disease, Mevalonate pathway, Disease, Mia, Collateral damage, Ethanol, Mouse, Clutch (eggs), Growth, Pancreas, Pancreatic cancer, Pain, Metastasis, Nerve, Medical imaging

THE WOODLANDS, TX, May 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the successful completion of an animal study evaluating the ability of targeted nerve ablation to impact tumor metastases and growth.

Key Points: 
  • For the preclinical mouse study, two groups of mice received human pancreatic tumor cells (Mia PaCa2) into the pancreatic head region.
  • The experimental group received peri-pancreatic neural ablation (ethanol infusion over the pancreatic nerves) while the control group received no treatment.
  • Lori Bisson, Chief Executive Officer of Autonomix, commented, “The successful completion of this preclinical animal study and highly encouraging results, support the clinical literature suggesting that nerve fibers may be a pathway for cancer cell metastasis tumor growth.
  • It is possible our ablation technology might slow human pancreatic cancer growth and metastasis and may be investigated in future clinical studies.